Navigation Links
Renovis Reports Third Quarter 2007 Financial Results
Date:11/6/2007

SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Renovis, Inc. (Nasdaq: RNVS), a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases, today announced financial results for the third quarter ended September 30, 2007.

Revenue for the third quarter and the nine months ended September 30, 2007 was $1.3 million and $8.5 million, respectively, compared to $2.2 million and $8.3 million in the corresponding periods in 2006. All of the revenue earned in the three- and nine-month periods of 2007 related to our collaboration with Pfizer Inc. to research, develop and commercialize small molecules that target the vanilloid receptor, or VR1. The decrease in revenue in the three months ended September 30, 2007 resulted from a change in the amortization period for the upfront license payment that Renovis received from Pfizer in 2005 in connection with the initiation of the collaboration. Following the amendment of that agreement earlier this year to extend the term of the collaboration for an additional year, the amortization period for the upfront license payment was extended, reducing the amount of upfront license fee revenue recognized in each of the first three quarters of 2007. The increase in revenue in the nine months ended September 30, 2007 resulted primarily from the Company's recognition of milestone revenue of $4.5 million from Pfizer partially offset by a decrease in revenue resulting from the revised amortization period as described above. In the corresponding period in 2006 the Company earned $1.5 million in milestone revenue related to the Pfizer collaboration.

Research and development expens
'/>"/>

SOURCE Renovis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Renovis to Present at CIBC World Markets Healthcare Conference
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... its Oral Amphotericin B program.  The company recently ... work involving samples from HIV/AIDS patients exposed ... pre clinical studies and regulatory filings to move ... utilizing approximately $700,000 of funding and technological advice ...
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... Indoor spraying with the insecticide bendiocarb has dramatically decreased ... that insecticides remain a potent weapon for fighting malaria ... an entire class of mosquito-killing compounds, according to a ... The American Journal of Tropical Medicine and Hygiene ...
... Texas, Oct. 5, 2011 Luminex Corporation (NASDAQ: ... the National Marrow Donor Program – Be The Match to ... the chances of finding a match for the growing number ... 100 Luminex employees joined the National Marrow Donor Registry in ...
... ANN ARBOR, Mich., Oct. 5, 2011 Adeona Pharmaceuticals, Inc. ... medicines for serious central nervous system diseases, announced today that ... and Chairman, will provide a brief update on its Alzheimer,s ... of four featured companies at the invitation-only event on Tuesday ...
Cached Biology Technology:Scientists determine alternative insecticide dramatically reduces malaria transmission 2Scientists determine alternative insecticide dramatically reduces malaria transmission 3Scientists determine alternative insecticide dramatically reduces malaria transmission 4Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match® 2Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match® 3Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match® 4Adeona CEO to Present at the NYC Medtech Forum 2
(Date:10/17/2014)... release is available in German . ... a very few drugs. When treating overdoses, doctors are often ... especially difficult if there is a combination of drugs involved. ... and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux ... to find an answer to this question. "The task was ...
(Date:10/16/2014)... Virginia Institute of Marine Science have received a ... to identify the streams and wetlands most vulnerable ... help local governments and citizens conserve these important ... dataset of tidal-marsh observations first gathered by VIMS ... baseline can today,s researchers accurately map the slow ...
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
... today center for discovery, economic growth engine, innovation hub, ... prepared for the challenges that lie ahead? , Is America ... , People are our greatest asset how do we ... the fiscal crisis on America,s research enterprise? , , ...
... 2012. Researchers from the University of Maryland School of ... bone marrow in mice to help create tissue cells of ... a scientific step they hope may lead to potential new ... Parkinson,s or Alzheimer,s. The research in collaboration with the University ...
... July 3, 2012 Exposure to childhood maltreatment increases ... many negative consequences of these conditions. This new ... University, Canada, provides important insight into one of the ... expanded our previous work on the epigenetic regulation of ...
Cached Biology News:All Things Research 2012 roundtable discussion 2Study results: Adult stem cells from bone marrow 2Highlighting molecular clues to the link between childhood maltreatment and later suicide 2
... Analysis Note: The kit contains all the ... determination of NADPH-cytochrome c reductase activity in ... microsomes [endoplastic reticulum (ER)]. It has been ... such as liver, kidney, brain, spleen, and ...
... Strain Competent Cell Sets Sets of ... combinations The most common method ... coli is to use chemically competent ... in the laboratory, greater efficiency, reproducibility and ...
The Saturn 2200 answers your GC/MS questions with the CP-3800 GC and the 2000 Series Ion Trap MS! These components create a platform for the worlds most versatile GC and flexible MS. Both deliver une...
... DNA Methylation Kit uses a simplified procedure ... methylation analysis. The kit is based on ... between cytosine and sodium bisulfite where cytosine ... Methylation Kits innovative in-column desulphonation reaction eliminates ...
Biology Products: